BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 30464534)

  • 1. OCT4, SOX2, and NANOG positive expression correlates with poor differentiation, advanced disease stages, and worse overall survival in HER2
    Yang F; Zhang J; Yang H
    Onco Targets Ther; 2018; 11():7873-7881. PubMed ID: 30464534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of Cancer Stem-Cell Markers OCT4, SOX2, and NANOG with Clinicopathological Features and Prognosis in Operative Patients with Rectal Cancer.
    You L; Guo X; Huang Y
    Yonsei Med J; 2018 Jan; 59(1):35-42. PubMed ID: 29214774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OCT4 but not SOX2 expression correlates with worse prognosis in surgical patients with triple-negative breast cancer.
    Zhang JM; Wei K; Jiang M
    Breast Cancer; 2018 Jul; 25(4):447-455. PubMed ID: 29536377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of OCT4, SOX2, and NANOG expression with oral squamous cell carcinoma progression.
    Fu TY; Hsieh IC; Cheng JT; Tsai MH; Hou YY; Lee JH; Liou HH; Huang SF; Chen HC; Yen LM; Tseng HH; Ger LP
    J Oral Pathol Med; 2016 Feb; 45(2):89-95. PubMed ID: 26211876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of High Expression Levels of SOX2, NANOG, and OCT4 in Gastric Cancer Tumor Tissues with Progression and Poor Prognosis.
    Basati G; Mohammadpour H; Emami Razavi A
    J Gastrointest Cancer; 2020 Mar; 51(1):41-47. PubMed ID: 30628031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of whole blood SOX2, NANOG and OCT4 mRNA expression in advanced small-cell lung cancer.
    Sodja E; Rijavec M; Koren A; Sadikov A; Korošec P; Cufer T
    Radiol Oncol; 2016 Jun; 50(2):188-96. PubMed ID: 27247551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic evaluation of Nanog, Oct4, Sox2, PCNA, Ki67 and E-cadherin expression in gastric cancer.
    Li N; Deng W; Ma J; Wei B; Guo K; Shen W; Zhang Y; Luo S
    Med Oncol; 2015 Jan; 32(1):433. PubMed ID: 25491144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Embryonic stem cells markers SOX2, OCT4 and Nanog expression and their correlations with epithelial-mesenchymal transition in nasopharyngeal carcinoma.
    Luo W; Li S; Peng B; Ye Y; Deng X; Yao K
    PLoS One; 2013; 8(2):e56324. PubMed ID: 23424657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [LincRNA-ROR functions as a ceRNA to regulate Oct4, Sox2, and Nanog expression by sponging miR-145 and its effect on biologic characteristics of colonic cancer stem cells].
    Yan ZY; Sun XC
    Zhonghua Bing Li Xue Za Zhi; 2018 Apr; 47(4):284-290. PubMed ID: 29690669
    [No Abstract]   [Full Text] [Related]  

  • 10. Relative Expression of OCT4, SOX2 and NANOG in Oral Squamous Cell Carcinoma Versus Adjacent Non- Tumor Tissue.
    Baghai Naini F; Aminishakib P; Abdollahi A; Hodjat M; Mohammadpour H; Kardouni Khoozestani N
    Asian Pac J Cancer Prev; 2019 Jun; 20(6):1649-1654. PubMed ID: 31244283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased Expression of Oct4, Nanog and CD24 Predicts Poor Response to Chemo-Radiotherapy and Unfavourable Prognosis in Locally Advanced Oral Squamous Cell Carcinoma.
    Mishra S; Tiwari V; Arora A; Gupta S; Anand N; Husain N
    Asian Pac J Cancer Prev; 2020 Sep; 21(9):2539-2547. PubMed ID: 32986350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Significance of the Pluripotency Factors NANOG, SOX2, and OCT4 in Head and Neck Squamous Cell Carcinomas.
    Pedregal-Mallo D; Hermida-Prado F; Granda-Díaz R; Montoro-Jiménez I; Allonca E; Pozo-Agundo E; Álvarez-Fernández M; Álvarez-Marcos C; García-Pedrero JM; Rodrigo JP
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32635524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of embryonal stem cell transcription factors in breast cancer: Oct4 as an indicator for poor clinical outcome and tamoxifen resistance.
    Gwak JM; Kim M; Kim HJ; Jang MH; Park SY
    Oncotarget; 2017 May; 8(22):36305-36318. PubMed ID: 28422735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung adenocarcinoma resistance to therapy with EGFR‑tyrosine kinase inhibitors is related to increased expression of cancer stem cell markers SOX2, OCT4 and NANOG.
    Hu F; Li C; Zheng X; Zhang H; Shen Y; Zhou L; Yang X; Han B; Zhang X
    Oncol Rep; 2020 Feb; 43(2):727-735. PubMed ID: 31894290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STAT3 correlates with stem cell-related transcription factors in cervical cancer.
    Wang H; Cai HB; Chen LL; Zhao WJ; Li P; Wang ZQ; Li Z
    J Huazhong Univ Sci Technolog Med Sci; 2015 Dec; 35(6):891-897. PubMed ID: 26670442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of SOX2, NANOG and OCT4 in a mouse model of lipopolysaccharide-induced acute uterine injury and intrauterine adhesions.
    Xiao L; Song Y; Huang W; Yang S; Fu J; Feng X; Zhou M
    Reprod Biol Endocrinol; 2017 Mar; 15(1):14. PubMed ID: 28253866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High expression of Oct4 and Nanog predict poor prognosis in intrahepatic cholangiocarcinoma patients after curative resection.
    Zhang MX; Gan W; Jing CY; Zheng SS; Yi Y; Zhang J; Xu X; Lin JJ; Zhang BH; Qiu SJ
    J Cancer; 2019; 10(5):1313-1324. PubMed ID: 30854141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of Oct4 and Sox2 and their clinical significance in tongue squamous cell carcinoma].
    Jiang XD; Luo G; Wang XH; Chen LL; Ke X; Li Y
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2017 Jan; 52(1):27-33. PubMed ID: 28072991
    [No Abstract]   [Full Text] [Related]  

  • 19. Significant association of combination of OCT4, NANOG, and SOX2 gene polymorphisms in susceptibility and response to treatment in North Indian breast cancer patients.
    Tulsyan S; Agarwal G; Lal P; Mittal B
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1065-78. PubMed ID: 25223935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OCT4 and SOX2 Specific Cytotoxic T Cells Exhibit Not Only Good Efficiency but Also Synergize PD-1 Inhibitor (Nivolumab) in Treating Breast Cancer Stem-Like Cells and Drug-Resistant Breast Cancer Mice.
    Peng W; Chang L; Li W; Liu Y; Zhang M
    Front Oncol; 2022; 12():781093. PubMed ID: 35402219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.